pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MRNAModerna, Inc.

$MRNA174.38+176.97%
Cambridge, MA, USupdated 3h ago

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
18
marketed
5
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(18)

view full pipeline →
pipeline depth18 products
Phase 1: 5Phase 2: 5Phase 3: 1Marketed: 5pre_registration: 2
5Phase 15Phase 21Phase 35Marketed2pre_registration
Marketed
Coronavirus Disease 2019 (COVID-19) KP.2 vaccine
Coronavirus Disease 2019 (COVID-19)
Marketed
Coronavirus Disease 2019 (SARS-CoV-2) vaccine 2
Coronavirus Disease 2019 (COVID-19)
Marketed
davesomeran + elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
mNEXSPIKE
Coronavirus Disease 2019 (COVID-19)
Phase 3
mRNA-1403
Norovirus Infections
Phase 2
intismeran autogene
Metastatic Melanoma
Phase 2
mRNA-3705
Methylmalonic Acidemia
Phase 2
mRNA-3927
Propionic Acidemia
Phase 2
mRNA-4359
Solid Tumor
Phase 2
respiratory syncytial virus vaccine
Respiratory Syncytial Virus (RSV) Infections
Fusion glycoprotein F0
Phase 1
mRNA-1215
Nipah Virus (NiV) Infections

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Jul 31, 2026
earnings
$MRNA174.38+176.97%
20d ago
Moderna, Inc. earnings
Moderna, Inc.
→
view all catalysts →

Wall Street consensus

source: yahoo finance · 20 analysts
mean target
$46.10
vs $49.56 now
implied upside
-7.0%
range: $21.00 – $135.00
consensus rating
Hold
2.96 / 5.0
rating distribution · 23 analysts
1
2
17
1
2
strong buystrong sell

recent actions (2)

  • Apr 2, 26REITBarclays→ Equal-Weight
  • Feb 23, 26REITPiper Sandler→ Overweight

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 2, 26SELLKlinger Shannon Thyme· Chief Legal Officer13,885 sh @ $52.29−$726K↗
  • Feb 23, 26SELLHoge Stephen· President160,009 sh @ $48.84−$7.81M↗
routine RSU / option mechanics (6)
  • Apr 2, 26tax coverMock James M · Chief Financial Officer703 sh
  • Apr 2, 26option exerciseMock James M · Chief Financial Officer1,453 sh
  • Apr 2, 26option exerciseMock James M · Chief Financial Officer1,453 sh
  • Mar 5, 26tax coverMock James M · Chief Financial Officer5,704 sh
  • Mar 5, 26tax coverKlinger Shannon Thyme · Chief Legal Officer5,704 sh
  • Mar 5, 26option exerciseMock James M · Chief Financial Officer11,797 sh
🐶 Hiring Signal
190 open roles at Moderna, Inc. →

Where Moderna, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaInfectious Disease & Vaccines 12Oncology 11Immunology & Inflammation 3CNS / Neuroscience 1
departmentIT & Engineering 40R&D / Discovery 25Manufacturing / CMC 20Regulatory 13Quality 12Market Access 6

News

  • Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts
    If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
    biospace · 5h ago
  • STAT+: Experts scrutinize Huidagene’s disclosures after patient death
    Merck and Moderna's mRNA cancer vaccine, an expected nominee to lead the FDA, and more biotech news from The Readout
    stat · 7h ago
  • STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
    A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
    stat · 7h ago
  • STAT+: American Cancer Society cancels alcohol industry fundraiser
    The American Cancer Society had an optics problem: its annual Wine and Spirits Industry's Gala. It decided to do something about it.
    stat · 9h ago
  • STAT+: Brain organoids, kept alive more than five years, matured like human brains
    Brain organoids kept alive more than five years continued to develop and mature, and showed molecular and genetic signatures like those of human brains.
    stat · 9h ago
  • Kolon TissueGene cuts 37 US staffers after Phase 3 fail
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 11h ago
  • 11 companies hiring in New Jersey
    Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.
    biospace · 11h ago
  • Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
    Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
    biospace · 11h ago
  • STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
    President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner
    stat · 11h ago
  • Dissecting Chinese trial strategy in wake of deaths
    Cancer "vaccine" successfully slowed melanoma, dissecting Chinese trial strategy in wake of deaths, and more health news from Morning Rounds
    stat · 13h ago
view all news mentions →
identifiers
ticker
$MRNA
SEC CIK
0001682852
country
US
source
sec_tickers
top tags
Infectious Disease13Oncology3Colorectal Cancer1NSCLC1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 33m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?